| Authors: |
Coombes RC; Imperial College, South Kensington, London, UK., Howell S; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Lord SR; Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK., Kenny L; Imperial College, South Kensington, London, UK., Mansi J; Guy's and St Thomas' NHS Foundation Trust, London, UK., Mitri Z; OHSU Knight Cancer Institute, Portland, OR, USA., Palmieri C; University of Liverpool, Liverpool, UK., Chap LI; University of California, Los Angeles, CA, USA., Richards P; Blue Ridge Cancer Center, Salem, VA, USA., Gradishar W; Northwestern University, Chicago, IL, USA., Sardesai S; US Oncology Research, OHC, Cincinnati, OH, USA., Melear J; Baylor University Medical Center, Texas Oncology, Dallas, TX, USA., O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, Dallas, TX, USA., Ward P; US Oncology Research, OHC, Cincinnati, OH, USA., Chalasani P; University of Arizona Cancer Center, Tucson, AZ, USA., Arkenau T; Sarah Cannon Research Institute, London, UK., Baird RD; Cancer Research UK Cambridge Centre, Cambridge, UK., Jeselsohn R; Dana-Farber Cancer Institute, Boston, MA, USA., Ali S; Imperial College, South Kensington, London, UK., Clack G; Carrick Therapeutics, Dublin, Ireland., Bahl A; Carrick Therapeutics, Dublin, Ireland., McIntosh S; Carrick Therapeutics, Dublin, Ireland., Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. matthew.krebs@manchester.ac.uk. |
